ASP Isotopes Earnings Call Transcripts
Fiscal Year 2026
-
Helium supply disruptions are driving urgent expansion of South African production, with phase I ahead of schedule and phase II backed by $0.5B in U.S. funding. Commercialization of Silicon-28, Carbon-14, and Ytterbium-176 is expected by H1 2026, while regulatory and commercial milestones support growth in uranium enrichment and electronic gases.
-
ASP Isotopes detailed expansion plans across nuclear medicine, semiconductors, and nuclear fuels, highlighting new contracts, plant upgrades, and a pending spin-off. Regulatory progress and strategic supply chain moves position the company for significant growth in 2024.
Fiscal Year 2025
-
Transitioning to commercial operations, revenue surged 480% in 2025, with major product launches and U.S. expansion planned for 2026. EBITDA is targeted to exceed $300 million by 2031, driven by strong demand in isotopes, helium, and electronic gases.
-
Operational enrichment plants are producing commercial samples, with revenue growth in radiopharmaceuticals and major acquisitions advancing vertical integration. Cash position is strong, with new plant construction and IPO plans for Quantum Leap Energy underway.
-
Key achievements include first shipments of enriched silicon-28, a major MOU with Fermi for isotope production, and a new JSE listing. Strategic partnerships, strong cash reserves, and government engagement position the business for growth in critical materials and energy isotopes.
-
A strategic partnership between IsoBio, ASP, and PET Labs aims to resolve isotope supply chain challenges in radiotherapeutics, supporting rapid market growth and a robust pipeline of antibody-isotope conjugates. Expansion into the U.S. and further vertical integration are underway.
-
The company is rapidly expanding its isotope and helium production capabilities, integrating new acquisitions, and leveraging advanced enrichment technologies to address critical supply chain gaps in medical, semiconductor, and nuclear markets. Strong financials and government partnerships support ambitious growth plans, including a major spin-out and new plant construction.
-
The merger creates a unique, vertically integrated supplier of critical materials, combining expertise in isotope enrichment and high-concentration helium. The deal is expected to be highly accretive, with strong operational synergies, robust government support, and a clear path to over $300 million EBITDA by 2030.
Fiscal Year 2024
-
Major milestones include the successful enrichment of Ytterbium-176 and the start of commercial production at three plants. Strong cash reserves and growing demand for isotopes position the company for expansion, with free cash flow positive expected in H2 2025.
-
The company is rapidly expanding its isotope production capabilities, commissioning new plants in South Africa and planning further growth in Iceland and the U.S. It has secured key customer agreements in medical and semiconductor markets, and is advancing HALEU production for nuclear energy through strategic partnerships and proprietary technology.